Table 1.
Baseline patient characteristics of AMI cohorts
| ICD-10 | DRG | p† value | *T1MI-UCH | *ICD10-UCH | p† value | *DRG-UCH | p† value | |
|---|---|---|---|---|---|---|---|---|
| Total n | 1935 | 662 | 425 | 525 | 258 | |||
| Demographics | ||||||||
| Age (median) | 65.2 (sd=13.4) |
70.3 (sd=14.9) |
<0.001 | 63.7 (sd=13.8) |
63.3 (sd = 14.0) |
0.192 | 68.3 (sd=15.1) |
<0.001 |
| Female | 577 (29.8%) | 321 (48.5%) | <0.001 | 128 (30.1%) | 172 (32.8%) | 0.758 | 126 (48.8%) | <0.001 |
| White or Caucasian | 1497 (77.4%) | 492 (74.3%) | 0.095 | 226 (53.2%) | 278 (53.0%) | 0.571 | 136 (52.7%) | 0.649 |
| Cardiology Team | 1430 (73.9%) | 385 (58.2%) | <0.001 | 218 (51.3%) | 269 (51.2%) | 0.607 | 107 (41.5%) | 0.006 |
| Medical History | ||||||||
| Diabetes Mellitus | 713 (36.8%) | 273 (41.2%) | 0.041 | 185 (43.5%) | 220 (41.9%) | 0.405 | 103 (39.9%) | 0.104 |
| Hypertension | 1510 (78.0%) | 560 (84.6%) | 0.002 | 324 (76.2%) | 400 (76.2%) | 0.963 | 213 (82.6%) | 0.084 |
| Hyperlipidemia | 1333 (68.9%) | 373 (56.3%) | <0.001 | 216 (50.8%) | 259 (49.3%) | 0.459 | 102 (39.5%) | 0.004 |
| Heart Failure | 646 (33.4%) | 347 (52.4%) | <0.001 | 169 (39.8%) | 211 (40.2%) | 0.242 | 136 (52.7%) | <0.001 |
| Peripheral Artery Disease | 78 (4.0%) | 24 (3.6%) | 0.305 | 15 (3.5%) | 15 (2.9%) | 0.311 | 1 (0.4%) | 0.012 |
| Prior Stroke | 330 (17.05%) | 167 (25.2%) | <0.001 | 81 (19.1%) | 103 (19.6%) | 0.325 | 58 (22.5%) | 0.332 |
| COPD | 288 (14.9%) | 138 (20.9%) | <0.001 | 68 (16.0%) | 87 (16.6%) | 0.818 | 61 (23.6%) | 0.010 |
| Chronic Kidney Disease | 487 (25.2%) | 279 (42.2%) | <0.001 | 118 (27.8%) | 166 (31.6%) | 0.189 | 122 (47.3%) | <0.001 |
| Dementia | 67 (3.5%) | 65 (9.8%) | <0.001 | 11 (2.6%) | 16 (3.1%) | 0.603 | 26 (10.1%) | <0.001 |
| Cancer | 356 (18.4%) | 137 (20.7%) | 0.235 | 61 (14.4%) | 81 (15.4%) | 0.470 | 52 (20.2%) | 0.009 |
| Home Medications | ||||||||
| Aspirin | 149 (7.7%) | 100 (15.1%) | <0.001 | 42 (9.9%) | 55 (10.5%) | 0.999 | 48 (18.6%) | <0.001 |
| P2Y12 Inhibitor | 91 (4.7%) | 52 (7.9%) | <0.001 | 30 (7.1%) | 36 (6.9%) | 0.279 | 23 (8.91%) | 0.548 |
| Beta Blocker | 172 (8.9%) | 112 (16.9%) | <0.001 | 58 (13.7%) | 68 (13.0%) | 0.116 | 54 (20.9%) | 0.049 |
| Any Statin | 172 (8.9%) | 99 (15.0%) | <0.001 | 53 (12.5%) | 64 (12.2%) | 0.715 | 47 (18.2%) | 0.085 |
| ACEi, ARB, ARNI | 152 (7.9%) | 81 (12.2%) | <0.001 | 51 (12.0%) | 58 (11.1%) | 0.159 | 43 (16.7%) | 0.265 |
| Oral Anticoagulation | 34 (1.8%) | 32 (4.8%) | <0.001 | 10 (2.4%) | 14 (2.7%) | 0.999 | 16 (6.2%) | 0.003 |
*
Subgroup analysis of all patients cared for at the University of Colorado Hospital (UCH).
†
Reference group for the main study cohort was ICD-10; reference group for the UCH subgroup was T1MI (T1MI-UCH).
Abbreviations: ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin-receptor blocker; ARNI = angiotensin-receptor neprilysin inhibitor; COPD = chronic obstructice pulmonary disease; DOAC = direct oral anticoagulant; DRG = Diagnosis Related Group; ICD-10 = international classification of diseases, 10th revision; T1MI = Type 1 myocardial infarction